MAPT and Alzheimer disease: Since plasma p-tau231 has been shown recently to be the earliest marker of amyloid aggregation (Mila-Aloma et al., 2022), it will be interesting to determine if p-tau231 affects tau phosphorylation and propagation across the entire AD spectrum.